Vaxcyte, Inc. (PCVX)

NASDAQ

$44.34

-$0.16 (0.36%)

Today

No price data available for this timeframe.

Key Statistics

Day Range

$43.34$44.77

Open $44.59

52 Week Range

$27.66$93.77

Previous Close $44.50

Market Cap5.80B

Volume1.06M

Avg Volume1.71M

P/E (TTM)-9.19

EPS (TTM)$-4.83

Dividend / YieldN/A

Dividend StreakN/A

Latest Press Releases for Vaxcyte, Inc.

DEC82025

Vaxcyte Doses First Participants in the OPUS Phase 3, Noninferiority Trial Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults

Source: GlobeNewsWire•7 days ago

Trial Design Finalized in Consultation and Alignment with U.S. Food and Drug Administration Study Designed to Establish a New Standard for Adult Pneumococcal Conjugate Vaccines Through Head-to-Head Safety, Tolerability and Immunogenicity Comparisons...

NOV42025

Vaxcyte Reports Third Quarter 2025 Financial Results and Provides Business Update Including Final Data from Positive VAX-24 Infant Phase 2 Dose-Finding Study

Source: GlobeNewsWire•41 days ago

Final Data from VAX-24 Infant Phase 2 Dose-Finding Study Consistent with Previously Reported Positive Interim Data; Provide Additional Evidence Supporting Higher VAX-31 Doses Being Evaluated in Ongoing Infant Phase 2 Study...

SEP302025

Vaxcyte to Establish Fill-Finish Manufacturing in North Carolina as Key Element of Long-Term United States Commercial Supply Strategy Representing Up to $1 Billion in Manufacturing and Services

Source: GlobeNewsWire•76 days ago

New Agreement with Thermo Fisher Scientific Expands Domestic Capacity to Support Future Commercial Manufacturing of Vaxcyte's Broad-Spectrum Pneumococcal Conjugate Vaccine Candidates...